Stryker Co. (NYSE:SYK) Stock Position Lifted by Tidal Investments LLC

Tidal Investments LLC boosted its position in Stryker Co. (NYSE:SYK - Free Report) by 13.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,478 shares of the medical technology company's stock after acquiring an additional 2,139 shares during the quarter. Tidal Investments LLC's holdings in Stryker were worth $6,314,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Dunhill Financial LLC grew its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the period. Centennial Bank AR grew its stake in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after buying an additional 48 shares during the period. Darwin Wealth Management LLC purchased a new stake in Stryker during the third quarter worth approximately $36,000. HBW Advisory Services LLC acquired a new stake in shares of Stryker in the third quarter worth $42,000. Finally, Hara Capital LLC purchased a new position in shares of Stryker in the 3rd quarter valued at $42,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In other news, VP M Kathryn Fink sold 7,347 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. This represents a 42.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

SYK has been the subject of several recent research reports. UBS Group increased their price target on Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. increased their target price on Stryker from $375.00 to $420.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. StockNews.com upgraded Stryker from a "hold" rating to a "buy" rating in a report on Wednesday. Barclays upped their price target on Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. Finally, Evercore ISI lifted their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $404.35.

Stryker Stock Down 0.1 %

NYSE SYK traded down $0.46 on Friday, hitting $374.60. 755,824 shares of the stock traded hands, compared to its average volume of 1,204,386. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average of $373.36 and a 200 day moving average of $354.92. Stryker Co. has a twelve month low of $285.79 and a twelve month high of $398.20. The company has a market capitalization of $142.81 billion, a P/E ratio of 40.15, a price-to-earnings-growth ratio of 2.82 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter last year, the business posted $2.46 EPS. Stryker's quarterly revenue was up 11.9% compared to the same quarter last year. As a group, analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Tuesday, December 31st. This is an increase from Stryker's previous quarterly dividend of $0.80. Stryker's dividend payout ratio is currently 34.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.